TY - JOUR T1 - Initiating antiretroviral therapy in HIV-infected patients with >500 CD4 cells/µL provides more benefit than delaying treatment JF - Evidence Based Medicine JO - Evid Based Med SP - 26 LP - 26 DO - 10.1136/ebmed-2015-110307 VL - 21 IS - 1 AU - George W Rutherford AU - Andrew Anglemyer Y1 - 2016/02/01 UR - http://ebm.bmj.com/content/21/1/26.abstract N2 - Commentary on: The INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015;373:795–807.OpenUrlCrossRefPubMedIt is clear that the successful treatment of HIV infection requires that patients be diagnosed, be engaged in regular care and receive and adhere to effective antiretroviral therapy (ART). When to start ART has been less clear. WHO guidelines have evolved over time from reserving therapy for the most immunocompromised in September 2015 treating all patients with HIV infection.1 Two large well-conducted randomised controlled trials (RCTs), the Strategic Timing of Antiretroviral Therapy (START) trial2 and the TEMPRANO ANRS 12136,3 have been particularly important in advancing the evidence base for universal therapy.START was designed and conducted by the International Network for Strategic Initiatives … ER -